deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00068718

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial

Sponsor: Fred Hutchinson Cancer Center

Conditions Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma
Interventions Therapeutic Allogeneic Lymphocytes
Updated 13 times since 2017 Last updated: Jan 15, 2020 Started: May 31, 2003 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Recurrent Adult Acute Lymphoblastic Leukemia and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 13 recorded versions since 2003 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jul 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations